According to a public notice released by the firm, drug producer Abbott India is recalling a batch of medicine intended to treat hypothyroidism owing to a labelling error.
The Thyronorm pill manufacturer, located in Mumbai, announced it is voluntarily recalling one batch of product that was produced in March of this year. The medicine manufacturer explained that this was caused by a labelling error in a tiny fraction of bottles from this batch, which was incorrectly branded with the dosage strength as 25 mcg while the bottles really contained 88 mcg tablets.
Only Madhya Pradesh and Telangana have received invoices for the batch, it was said.
Patients who recently purchased Thyronorm with batch number AEJ0713 are asked to either return the bottle to the pharmacy where they bought it or contact the manufacturer, according to a statement from Abbott India.
When approached about the situation on Thursday, the pharmaceutical company acknowledged the development and highlighted that the recall is the result of a labelling error and the product is in perfect condition.
"We haven't heard of any patient effect complaints. A few bottles of the 88 mcg tablet batch (No. AEJ0713) in question had inaccurate 25 mcg labels. We have started a voluntary recall of the batch that was mislabeled since it is crucial that individuals take the proper dosage, it said.
To enable this recall, the business is collaborating with its distributors and other partners, it noted.
"Only MP and Telangana have received invoices for this batch. Thyronorm or any other batch or dose strength of Abbott products are unaffected or not affected by this problem, according to the business.
© Copyright 2023. All Rights Reserved Powered by Vygr Media.
